Anti-BCMA CAR Lentivirus (Clone C11D5.3 ScFv-CD8-4-1BB-CD3ζ) | 78655

Anti-BCMA CAR Lentivirus (Clone C11D5.3 ScFv-CD8-4-1BB-CD3ζ) | 78655 | Gentaur US, UK & Europe Disrtribition

Category: CAR-T/Lentivirus

Application: Positive control for anti-BCMA CAR evaluation in T cells Transduction optimization studies

Background: B-cell maturation antigen (BCMA), also known as CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and on Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy because of its restricted expression in nonmalignant tissue but almost universal expression on MM cells. To date, the FDA has approved two BCMA CAR-T therapies for the treatment of multiple myeloma.

Description: The anti-BCMA CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragment) of anti-BCMA (clone C11D5.3) linked to a 2^nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (Figure 1). The lentiviruses also transduce a puromycin selection gene.

Product Type: Lentivirus

Shippement Condition: -80°C